Recently added

White paper on best practices for translational research in neuroendocrine neoplasms

Cros, Jerome; Casanovas, Oriol; Castaño, Justo P.; Dayton, Talya; GIBERT, Benjamin; Garcia-Alvarez, Alejandro (Wiley, 2025-10)

Differentiating low tumor burden from oligometastatic disease in colorectal cancer: a call for individualized therapeutic approaches

De Grandis, Maria Caterina; Elez, Elena; Baraibar, Iosune; Prior, Olivia; Balaguer-Montero, Maria; Salvà, Francesc; Ros, Javier; R Castells, Marta; Tabernero, Josep; Perez-Lopez, Raquel (Elsevier, 2025-08)

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer

He, Jianxing; Tsuboi, Masahiro; Weder, Walter; Chen, Keneng; Hochmair, Maximilian; Shih, Jin-Yuan; MARTINEZ-MARTI, ALEX (American Society of Clinical Oncology, 2025-09-10)

Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, Italy, and Germany

Potthoff, Karin M.; Procaccio, Letizia; Yoo, Changhoon; Hédouin-Biville, Fabienne; Lonardi, Sara; Macarulla, Teresa (Elsevier, 2025-09)

Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer

Mountzios, Giannis; de Marinis, Filippo; Paz-Ares, Luis; Juan-Vidal, Oscar; FELIP, ENRIQUETA; Reinmuth, Niels (Taylor & Francis, 2025-10)

Scientia. Department of Health Digital Information Depot

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

White paper on best practices for translational research in neuroendocrine neoplasms

Differentiating low tumor burden from oligometastatic disease in colorectal cancer: a call for individualized therapeutic approaches

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer

Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, Italy, and Germany

Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer

Scientia. Department of Health Digital Information Depot

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

White paper on best practices for translational research in neuroendocrine neoplasms ﻿

Differentiating low tumor burden from oligometastatic disease in colorectal cancer: a call for individualized therapeutic approaches ﻿

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer ﻿

Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, Italy, and Germany ﻿

Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer ﻿

White paper on best practices for translational research in neuroendocrine neoplasms

Differentiating low tumor burden from oligometastatic disease in colorectal cancer: a call for individualized therapeutic approaches

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer

Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, Italy, and Germany

Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer